Beyond Air, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Beyond Air, Inc. (XAIR) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$219.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-13
- Beyond Air, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$219.00K.
- Beyond Air, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$86.00K.
- Beyond Air, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$294.00K.
- Beyond Air, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$318.00K.
- Beyond Air, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2026 was -$1.08M.
- Beyond Air, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$1.85M.
- Beyond Air, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$4.05M.
- Beyond Air, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$3.58M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$219.00K 10-Q · filed 2026-08-13 | -$305.00K derived: sum of 2 quarters · filed 2026-08-13 | -$599.00K derived: sum of 3 quarters · filed 2026-08-13 | -$917.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-26 | -$380.00K derived: sum of 2 quarters · filed 2026-06-26 | -$698.00K derived: sum of 3 quarters · filed 2026-06-26 | -$1.08M 10-K · filed 2026-06-26 |
| 2025-12-31 | -$294.00K 10-Q · filed 2026-02-13 | -$612.00K derived: sum of 2 quarters · filed 2026-02-13 | -$999.00K 10-Q · filed 2026-02-13 | -$1.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | -$318.00K 10-Q · filed 2025-11-10 | -$705.00K 10-Q · filed 2025-11-10 | -$734.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$387.00K 10-Q · filed 2026-08-13 | -$416.00K derived: sum of 2 quarters · filed 2026-08-13 | -$716.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-26 | -$329.00K derived: sum of 2 quarters · filed 2026-06-26 | -$1.00M derived: sum of 3 quarters · filed 2026-06-26 | -$1.85M 10-K · filed 2026-06-26 |
| 2024-12-31 | -$300.00K 10-Q · filed 2026-02-13 | -$971.00K derived: sum of 2 quarters · filed 2026-02-13 | -$1.82M 10-Q · filed 2026-02-13 | -$2.67M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | -$671.00K 10-Q · filed 2025-11-10 | -$1.52M 10-Q · filed 2025-11-10 | -$2.37M derived: sum of 3 quarters · filed 2025-11-10 | -$3.41M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$854.00K 10-Q · filed 2025-08-12 | -$1.70M derived: sum of 2 quarters · filed 2025-08-12 | -$2.74M derived: sum of 3 quarters · filed 2025-08-12 | -$3.95M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$849.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-20 | -$1.89M derived: sum of 2 quarters · filed 2025-06-20 | -$3.09M derived: sum of 3 quarters · filed 2025-06-20 | -$4.05M 10-K · filed 2025-06-20 |
| 2023-12-31 | -$1.04M 10-Q · filed 2025-02-10 | -$2.24M derived: sum of 2 quarters · filed 2025-02-10 | -$3.20M 10-Q · filed 2025-02-10 | -$4.19M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-09-30 | -$1.21M 10-Q · filed 2024-11-12 | -$2.17M 10-Q · filed 2024-11-12 | -$3.15M derived: sum of 3 quarters · filed 2024-11-12 | -$4.20M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$960.00K 10-Q · filed 2024-08-06 | -$1.94M derived: sum of 2 quarters · filed 2024-08-06 | -$3.00M derived: sum of 3 quarters · filed 2024-08-06 | -$3.83M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$984.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-24 | -$2.04M derived: sum of 2 quarters · filed 2024-06-24 | -$2.87M derived: sum of 3 quarters · filed 2024-06-24 | -$3.58M 10-K · filed 2024-06-24 |
| 2022-12-31 | -$1.05M 10-Q · filed 2024-02-12 | -$1.88M derived: sum of 2 quarters · filed 2024-02-12 | -$2.60M 10-Q · filed 2024-02-12 | -$3.26M derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-09-30 | -$830.00K 10-Q · filed 2023-11-13 | -$1.55M 10-Q · filed 2023-11-13 | -$2.21M derived: sum of 3 quarters · filed 2023-11-13 | -$2.43M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$720.00K 10-Q · filed 2023-08-10 | -$1.38M derived: sum of 2 quarters · filed 2023-08-10 | -$1.60M derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$659.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-22 | -$882.00K derived: sum of 2 quarters · filed 2023-06-22 | -$882.00K 10-K · filed 2023-06-22 | |
| 2021-12-31 | -$223.00K 10-Q · filed 2023-02-10 | -$223.00K 10-Q · filed 2023-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |